AI integrated into molecular profiling workflows identified misclassified lung cancer cases, highlighting its potential role in improving diagnostic accuracy in clinical labs.
The clearance of the Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay aim to reduce barriers for unscreened populations.
Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Read More
A novel enrichment method produces virtually pure circulating tumor DNA from blood samples, showing strong sensitivity and specificity across colorectal and lung cancer patients.
Read More
Preoperative blood testing using H3K27Me3-nucleosome levels may help clinicians identify which non-small cell lung cancer patients need closer follow-up or additional treatment.
Read More
A combined clinicopathologic and gene expression profile test identified high-risk sentinel lymph node metastasis in T1a melanoma patients with greater specificity than standard tools.
Read More
A pooled analysis of more than 1,100 patients across four cohort studies supports the clinical utility of the Nodify CDT test in identifying high-risk lung nodules.
Read More
A study found that circulating tumor DNA testing detected residual disease signals missed by conventional prognostic measures in patients with breast cancer.
Read More
The collaboration has produced a custom nucleic acid extraction workflow designed to unlock molecular insights from a novel biospecimen and improve diagnostic utility in gut health conditions.
Read More
Ibex Medical Analytics has launched Ibex 4, an AI-powered pathology platform with expanded end-to-end breast cancer diagnostic workflows, zero-click IHC tools, and enhanced lab integration capabilities for increased efficiency.
Read More
The Pennsylvania-based laboratory will integrate Ibex’s AI solution for prostate biopsies and TURP specimens into its existing digital pathology infrastructure.
Read More
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
Read More
The Bloodhound BCR::ABL1 assay simultaneously detects and quantifies all four clinically important isoforms in a single run, offering new capabilities for chronic myeloid leukemia management.
Read More
The initiative gives eligible pharmacy customers a streamlined pathway to request the Cologuard stool DNA test, with no prep or special diet required.
Read More
Hepion Pharmaceuticals has licensed a circulating tumor RNA assay from Cirna Diagnostics for early detection of hepatocellular carcinoma in high-risk patients, expanding its liquid biopsy portfolio for liver cancer.
Read More
20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.
Read More
Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More